Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
New Zealand Fast-Tracks Gold Mining as Industry Revival Gains Momentum 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
U.S.-Iran Diplomacy Helps Drive Gasoline Prices Down 15% From May Highs 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Oil Prices Slip as Iran Sanctions Relief and Hormuz Shipping Recovery Ease Supply Concerns 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
